Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B‑cell lymphoma
Opioid exposure during cancer treatment is common and leads to new persistent opioid use (NPOU) in a subset of patients.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers